ITD Study (AMaRC 16-02)
A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.
The primary purpose of this trial is to evaluate the safety and efficacy of a combination of ixazomib, thalidomide and dexamethasone (ITD) for the treatment of multiple myeloma which has progressed despite one to three lines of previous therapy.
More information available at:
Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)
Other (specify below)
Parts of research done:
Literature review, Research proposal, Ethics approval, Data collection, Data analysis